A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Last 30 days: 145 accesses
Last 365 days: 1602 accesses
All time: 1602 accesses

Nicola Savill^* and Chris J Bushe

Child and Adolescent Psychiatry and Mental Health 2012, 6:2 doi:10.1186/1753-2000-6-2

Accesses